Therapeutic Vaccines Market by Product Type (Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, Toxoid Vaccines, Recombinant Vaccines), by Application (Infectious Diseases, Oncology, Addiction, Autoimmune Diseases, Neurological Diseases, Others), by Technology (Autologous Vaccines, Allogeneic Vaccines), by Valency (Monovalent vaccines, Multivalent vaccines), by End-user (Hospitals, Clinics, Others) and Geography

 

Therapeutic Vaccines Market size was valued at USD 28.4 billion in 2021 and is expected to reach USD 103.23 billion by 2028, at a CAGR of 18.03% during the forecast period 2022 to 2028. Therapeutic vaccines are biological combinations which develop immunity against a diseased tissue or cell. Therapeutic vaccines are administered to the patient in order to induce a defence mechanism against particular disease. These are developed to treat various cancer diseases, HIV, and Alzheimer’s disease etc. Prophylactic vaccines differ from therapeutic vaccines are used for the prevention and control of diseases, while the prophylactic vaccines are only used for prevention of diseases. Therapeutic vaccines are specially manufactured for the HIV positive individuals with the healthy immune system, to increase the ability to fight against microorganisms. Therapeutic vaccines are currently developed for chronic viral infections, such as human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), cancer, hepatitis B virus, and hepatitis C virus etc. as an alternative to antiviral treatment. The global therapeutic vaccines market is in the nascent stage where many players are actively involved in the development of therapeutic vaccines. Few companies have adopted some key business strategies, such as product innovation, and new product launching to ensure their dominance in the global therapeutic vaccines market. The global therapeutic vaccines market is positively affected by the significant rise in prevalence of chronic diseases such as cancer, and HIV etc. Few companies have taken an active lead in research and development of therapeutic vaccines. For instance, in April 2010, Dendreon Corporation, launched FDA approved immunotherapy drug Provenge, for the treatment of prostate cancer. According to U.S. Department of Health and Human Services, there are some vaccines in the clinical trial stage, such as Lucanix (Belagenpumatucel-L), gp100 melanoma vaccine, for Non-small cell lung cancer. Similarly, Merck & Co., Inc. and GSK Plc. are expected to launch vaccines such as GSK1572932A, and GV1001 having entered phase 3 trials.